Rovtidskriftsjägaren om sin ärkefiende: ”Ondskans imperium”

Han myntade begreppet rovtidskrifter och gjorde ett första försök att kartlägga deras utbredning. Nu berättar bibliotekarien Jeffrey Beall om konsekvenserna det...

She is CSL Behring's new Nordic General Manager

Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB.

New large lab building in Lund inaugurated – here are the companies moving in

Medicon Village has received a new laboratory building. On Friday last week the building was inaugurated with a ribbon-cutting ceremony by Minister for Employme...

”Bilder är det perfekta målet för AI”

Allt fler lösningar baserade på artificiell intelligens utvecklas och används i vården. Radiologi är ett område som lämpar sig väl för tekniken. Det menar Sophi...

Double up for Korbinian Löbmann

This year, Korbinian Löbmann will moderate the New Updates in Drug Formulation & Bioavailability meeting in Copenhagen for the fifth time. Furthermore, he will ...

Come see us at the upcoming events!

We have some upcoming events where you can see our latest products live!

A new giant among our microscopes

Two technologies in one machine.

Siemens köper forskningsplattform inom läkemedel för 51 miljarder

Siemens AG tar ett rejält kliv in på life science-området genom att förvärva amerikanska Dotmatics och dess forskningsplattform i en affär på 5,1 miljarder doll...

Innovative start-up helps doctors, scientists and industry balance coagulation risks

For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thro...

Studie: AI kan avslöja kommande demens

Ett nytt AI-program uppges kunna bedöma risken för framtida Alzheimersrelaterad demens – genom analys av personers tal.

Column: ”Life as a F1 race”

"The F1 car makes several pit stops during a race and during a lifetime the human being may also have to come in several times for maintenance", Björn Ursing wr...

Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...

The art of building a biologic drug

The first biosimilar from Xbrane Biopharma was launched earlier this year, and several more are under development at the company’s facility in Solna, Sweden. “W...

Hann du läsa det här? Redaktionen tipsar

Missade du vår rapportering om rovtidsskrifter, rankningen av Sveriges främsta forskare eller reportaget från KI:s zebrafiskakvarium? Inför sommarens lata dagar...

A surprising discovery about the immune system in cases of cancer

Professor Göran Jönsson is trying to understand why some patients benefit from immunotherapies while others don’t. A couple of years ago, he made a surprising d...

Non-destructive testing and assembly control

Assess complete assembly.

22 miljarder – så mycket kostar det att utveckla ett nytt läkemedel

Den genomsnittliga kostnaden för Big Pharma att ta ett läkemedel hela vägen från upptäckt till lansering var i fjol 2,23 miljarder dollar, motsvarande en bra bi...

Pharma Outsourcing – Find the Right Partner (2026)

Här är life science-företagen på Norrskens lista – ”Ett Nobelpris för entreprenörer”

Små robotar som levererar läkemedel till olika delar av kroppen. Det är ett av projekten som är med på Norrskens Impact 100-lista.

Speed meets precision for high-density components

ZEISS METROTOM 800 320 kV.

Artificial intelligence in radiology – “Risk prediction is very exciting”

A growing number of solutions based on artificial intelligence are being developed and used in healthcare. According to Sophia Zackrisson, Professor of Radiolog...

Merck Life Science A/S

Nordic Regulatory experts: Improving biotech chances of Succ

Why is it that so many biotech companies fail? And what are the tools needed to change that fact?

From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...